Sign inJoin waitlistJoin the waitlist

Eleonora Teplinsky

Hematology and Medical Oncology Fellowship Program Director · Icahn School of Medicine at Mount Sinai

Credentials: · · · · · ·

History

Hematology and Medical Oncology Fellowship · Icahn School of Medicine at Mount Sinai
Present
Breast and Gynecologic Medical Oncology Division · Valley-Mount Sinai Comprehensive Cancer Care
Present
The Icahn School of Medicine, Mount Sinai · Icahn School of Medicine at Mount Sinai
Present

New York University Medical Center
2012–2015
Hospital
2012–2015
Internal Medicine
Tufts Medical Center
2009–2012
Tufts University School of Medicine
2005–2009

Research

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Journal of Clinical Oncology · 2021 · 80 citations
Targeting HER2 in ovarian and uterine cancers: challenges and future directions
Review · Gynecologic Oncology · 2014 · First of 2 authors · 54 citations
Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy
Clinical Breast Cancer · 2016 · 52 citations

FE
Francisco Esteva
3 papers
FM
Franco Muggia
3 papers
KJ
Komal Jhaveri
3 papers
Kent Friedman
2 papers
LA
Laila Agrawal
2 papers
MM
Martina Murphy
2 papers
Merry-Jennifer Markham
2 papers
Shannon Westin
2 papers
Thomas Herzog
2 papers
Abby Rosenberg
1 paper
AA
Ajjai Alva
1 paper
Allison Magnuson
1 paper

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
E-Mindfulness Approaches for Living After Breast Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2030
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033

Honors

FASCO

valleyhealth.com